AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ETRA

GORDON CARL L purchased $3.6M of ETRA (indirect holdings)

GORDON CARL L purchased 472,571 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at an average of $7.63 ($7.07–$7.88, $3.61M total) across 10 trades over 2026-11-03 to 2026-11-05.

Original reporting
SEC EDGAR · GORDON CARL L
Published Nov 5, 2026, 10:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ETRA
Bullish
medium confidence
Mentioned
$ETRA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ETRABullishLow
01

Why it matters

The purchase adds credibility to the company's outlook and may influence short‑term price dynamics.

02

Market read

Insider activity is a primary catalyst for micro‑cap price movement.

03

What to watch

Potential upcoming clinical trial results or financing activities not disclosed yet.

Relevance 7/10Novelty 7/10Timing: after‑hours filing

Background

Form 4 filing reveals a director's recent purchase of 472,571 shares at an average price of $7.63.

Company-level read

Ticker impact

$ETRABullishMedium confidence
Context

Director Gordon Carl L purchased $3.6M of Electra Therapeutics shares, increasing his stake to 2.14M shares.

Expected impact

likely upward pressure as market prices in insider confidence

Evidence & confidence

A $3.6M open‑market buy by a director is material for a micro‑cap and may trigger short covering or buying interest.

Market effects

Sector

Biotech sector may see modest uplift as insider confidence is viewed positively.

Regional

U.S. biotech investors could react, no broader regional effect.

Global

Limited to investors tracking small‑cap biotech stocks.

Counterpoint

What could challenge this read

Insider buying could be a defensive move ahead of upcoming dilution or negative news.

Key entities

  • company
    Electra Therapeutics, Inc.

    Biotech firm developing gene‑editing therapies.

  • insider
    Gordon Carl L

    Director and 10% owner of Electra Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ETRA insider trading history →

Related articles

$ETRAMed

H.C. Wainwright initiates Electra stock coverage with buy rating

H.C. Wainwright initiated coverage on Electra Therapeutics (ETRA) with a buy rating and $30 price target, citing clinical progress and financial flexibility. The stock trades near its 52-week low at $8.71. Multiple analysts rate ETRA positively, highlighting its lead drug candidate, ipsoprubart, in trials for hemophagocytic lymphohistiocytosis. The company's upcoming IPO is expected to price above its $14-$16 range.

investing.com
$ETRAMed

JPMorgan initiates Electra stock at Overweight on sHLH drug potential

JPMorgan initiated coverage on Electra (NASDAQ:ETRA) with an Overweight rating and a $36.00 price target, implying 300% upside from the current $9.05. The firm's thesis is based on the potential of ipsoprubart, a drug in Phase 2/3 trials for secondary hemophagocytic lymphohistiocytosis (sHLH). Electra is preparing for an IPO priced between $14 and $16, with strong institutional demand.

investing.com